ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

ClinicalTrials.gov ID: NCT05936567

Public ClinicalTrials.gov record NCT05936567. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria

Study identification

NCT ID
NCT05936567
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
136 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 30, 2023
Primary completion
Feb 27, 2025
Completion
Oct 8, 2025
Last update posted
Mar 11, 2026

2023 – 2025

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
Clinical Research Center of Alabama Birmingham Alabama 35209
Cahaba Dermatology Birmingham Alabama 35244
Foothills Research Center Scottsdale Arizona 85260
Little Rock Allergy Asthma, Pa Clinical Research Center Lraac Little Rock Arkansas 72205
Arkansas Research Trials North Little Rock Arkansas 72117
First Oc Dermatology Fountain Valley California 92708
Newport Native Md Newport Beach California 92663
Antelope Valley Clinical Trials Lancaster Office Palmdale California 93551
Allergy and Asthma Consultants, Pc Redwood City California 94063
Treasure Valley Medical Research Boise Idaho 83706
Midwest Allergy Sinus Asthma, Sc Normal Illinois 61761
Delricht Research New Orleans Louisiana 70115
David Fivenson, Md, Dermatology, Pllc Ann Arbor Michigan 48103
Revival Research Institute, Llc Troy Troy Michigan 48084
The Clinical Research Center Crc, Llc St Louis Missouri 63141
Optimed Research Ltd Columbus Ohio 43235
Central Sooner Research Oklahoma City Oklahoma 73170
Vital Prospects Clinical Research Institute, Pc Vpcri Tulsa Oklahoma 74136
Dermdox Center For Dermatology Sugarloaf Pennsylvania 18249
Allergy and Asthma Center of Charleston Charleston South Carolina 29407
Rainey and Finklea Dermatology San Antonio Texas 78212
Bellingham Asthma, Allergy Immunology Clinic Bellingham Washington 98225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05936567, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 11, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05936567 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →